Please login to the form below

Not currently logged in
Email:
Password:

Amag

This page shows the latest Amag news and features for those working in and with pharma, biotech and healthcare.

Amag buys into maternal health business

Amag buys into maternal health business

Meanwhile, another key driver of the deal is thought to be the potential to push sales of Lumara's drug using Amag's commercial base. ... Under the terms of the acquisition, Lumara will operate as a separate business within Amag reporting to the Amag's

Latest news

  • Death leads to recall of batch of Takeda's Rienso in Switzerland Death leads to recall of batch of Takeda's Rienso in Switzerland

    As reported by Reuters, Amag's shares were down about 5 per cent following the recall announcement. ... Both Amag and Takeda are now investigating the Swiss batch of Rienso, while the introduction of new batches will depend on approval by Swiss health

  • Oncology bias in pharma deals

    Newron should receive a $2m termination fee from Biotie. The $179m merger between oncology company, Allos Therapeutics and AMAG Pharmaceuticals announced in July, was terminated when AMAG shareholders rejected the deal ... 2 ##. Allos Therapeutics/AMAG

  • Dermatology developments

    One of the Amag investors, the hedge fund MSMB, strongly opposed the merger and made a bid of $381m for Amag. ... Retin-A and Renova. Launched. 345. Amag/Allos. Amag merges with Allos, pays $268m to Allos shareholders.

  • Orphan drug focus

    318. AMAG Pharmaceuticals/ Takeda. feraheme (ferumoxytol) - for iron deficiency anaemia.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Acquisition - business unit. 1, 045. EndoCeutics/ AMAG Pharmaceuticals. Intraros (prasterone), non-oestrogen product for postmenopausal atrophic vaginitis (FDA approved), female sexual dysfunction (phase III).

  • Deal Watch January 2017 Deal Watch January 2017

    500. Palatin Technologies. AMAG Pharmaceutical. Exclusive licence for N. America. Rekynda (bremelanotide) for sexual disorder p3.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    1, 750. Lumara Health / Amag. Lumara Health / Perrigo. Company acquisition (excluding Perrigo products).

  • Pharma deals during September 2014 Pharma deals during September 2014

    Amag is buying the remaining company for up to $1.025bn. It contains Makena, a progesterone injection with US orphan status to reduce the risk of preterm birth with annual sales

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
integrated medhealth communication

imc group is a leading, independent global healthcare communication group that enables client’s brands to connect with healthcare professionals, payers...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...